Abstract
Cilostazol, a novel cyclic adenosine monophosphate phosphodiesterase type III inhibitor, has been developed as an antiplatelet drug with a vasodilating action on peripheral arteries. The present study was designed to test, in humans, whether cilostazol can dilate the epicardial coronary arteries and what are its hemodynamic effects. Eight patients with chest pain syndrome were subjected to serial quantitative coronary arteriography immediately before and at 30, 60 and 150min after a single oral dose of cilostazol (200mg). Luminal cross-sectional areas (mm2) at the proximal and distal sites of major coronary arteries (6 segments at each sampling time) were significantly increased at 150 min after taking the drug. The percent increases relative to the baseline values were 25+/-7 (6.8+/-0.8-->8.3+/-1.0*) and 42+/-7% (2.1+/-0.3-->3.0+/-0.4*) in the right coronary artery, 24+/-5 (5.1+/-0.7-->6.1+/-0.8*) and 28+/-10% (1.6+/-0.31-->9+/-0.3*) in the left anterior descending artery, and 14+/-6 (5.9+/-0.9-->6.6+/-0.9*) and 24+/-10% (1.3+/-0.2-->1.5+/-0.2*) in the left circumflex artery, respectively (*p<0.05 vs baseline). This action, relative to that of nitroglycerine, was between 27% and 54%. Moreover, small but sustained decreases in ...Continue Reading
References
Dec 1, 1992·Journal of Cardiovascular Pharmacology·S TakahashiS Miyabo
Jul 1, 1992·Archives of Internal Medicine·R B HaynesF M Yatsu
May 1, 1991·Circulation·P L ThompsonW F Walsh
Oct 1, 1989·Circulation·C H HennekensR Peto
Jan 1, 1988·Pharmacology·T TanakaH Hidaka
Oct 14, 1988·Biochemical and Biophysical Research Communications·C MaziereJ Polonovski
Sep 1, 1987·Catheterization and Cardiovascular Diagnosis·K H SilverA B Nichols
Mar 22, 1985·Journal of Chromatography·H AkiyamaT Shimizu
Mar 1, 1984·Circulation·A B NicholsP D Esser
Jan 1, 1995·American Journal of Respiratory and Critical Care Medicine·M FujimuraT Matsuda
Apr 1, 1996·Japanese Circulation Journal·M TsutsuiS Okamatsu
Jun 1, 1997·The American Journal of Cardiology·M OchiaiH Miyashita
Jan 7, 1998·Clinical Therapeutics·T KunishimaM Murayama
Jan 1, 1997·Life Sciences·N MinamiM Nishikawa
Apr 29, 1998·Journal of Clinical Pharmacology·A SuriS L Bramer
Apr 29, 1998·Journal of Cardiovascular Pharmacology·H AtarashiH Hayakawa
Aug 26, 1998·Circulation·D L DawsonD E Strandness
Jul 7, 1999·Circulation·E TsuchikaneN Awata
Oct 8, 1999·Journal of Cardiovascular Pharmacology·J ConeY Liu
Dec 22, 1999·The American Journal of Cardiology·Y YoonS Y Cho
Sep 22, 2000·Atherosclerosis·T TaniY Kimura
Sep 29, 2000·The American Journal of Cardiology·S W ParkS J Park
Nov 7, 2000·The American Journal of Medicine·D L DawsonD E Strandness
Jan 3, 2001·American Heart Journal·K KozumaT Tamura
Jan 11, 2001·Journal of Cardiovascular Pharmacology and Therapeutics·S ToyonagaT Tsuji
Feb 13, 2001·European Journal of Pharmacology·S TakaiM Miyazaki
Citations
Jun 19, 2013·Drugs·Eric P Brass
Jul 1, 2004·Circulation Journal : Official Journal of the Japanese Circulation Society·Makoto SekiguchiMasahiko Kurabayashi
Nov 11, 2009·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Shinichiro UchiyamaSun Uck Kwon
Oct 2, 2007·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Sebastián F AmerisoAntonio Ricardo La Mura
Sep 20, 2005·American Heart Journal·Yaling HanJunbo Ge
Jul 12, 2021·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Hao ZhouQian Liu
Oct 22, 2021·Journal of Clinical Pharmacology·Antonis A ManolisAntonis S Manolis